Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 17%
Buy 42%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is positioned favorably in the biopharmaceutical market due to its innovative approach with Bicycles, particularly its lead product candidate BT1718, which demonstrates promising efficacy and safety profiles in oncology. Feedback from key opinion leaders (KOLs) indicates a competitive advantage for the company's emerging therapies over existing treatments like Padcev, with potential treatment switches anticipated among current patients that could significantly enhance market penetration. Additionally, the company's investment appeal is bolstered by its strategic focus on radiopharmaceuticals alongside its advanced technologies that could improve tumor targeting and patient safety, underpinning optimism for future revenue growth.

Bears say

Bicycle Therapeutics PLC has experienced significant share price pressure, with a year-to-date decline of 45%, primarily due to uncertainties surrounding its product candidate Zelenectide's competitive positioning against Padcev. The company's clinical data has been perceived as equivocal, and potential efficacy and safety concerns could exacerbate investor sentiment, reflecting fears of a possible 25% downside. Additionally, the evolving landscape towards next-generation macrocyclic peptides, coupled with risks associated with intellectual property protection, threatens to diminish Bicycle Therapeutics's competitive stance and platform valuation.

BCYC has been analyzed by 12 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 42% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 12 analysts, BCYC has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.